Bacillus mojavensis VT275 and application thereof

Through the isolated Bacillus mohaivir VT275 from the skin of healthy children, the adverse drug reactions and pathogen resistance problems in the treatment of atopic dermatitis were solved, effective inhibition of pathogenic bacteria such as Staphylococcus aureus was achieved, and the application of microecological treatment was promoted.

CN120366126AActive Publication Date: 2025-07-25ZHEJIANG ACADEMY OF AGRICULTURE SCIENCES
9 Cites 0 Cited by

Patent Information

Application Number
CN202510506837.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-04-21
Publication Date
2025-07-25
Estimated Expiration
2045-04-21

AI Technical Summary

Technical Problem

In the prior art, in the treatment of atopic dermatitis, long-term use of drugs may cause adverse reactions, and the drug resistance of pathogens such as Staphylococcus aureus is difficult to solve, and microecological treatment methods are insufficient.

Method used

It provides a Bacillus mohaivir VT275 isolated from the skin of healthy children, which has a broad-spectrum inhibitory effect on pathogens such as Staphylococcus aureus. It is prepared into lyophilized preparations, capsule preparations and other forms to be used in medicines, cosmetics and foods for the prevention or treatment of atopic dermatitis and inhibition of foodborne pathogens.

Benefits of technology

Bacillus mohaivir VT275 significantly inhibits pathogenic bacteria such as Staphylococcus aureus, is safe and effective, and is suitable for the prevention and treatment of atopic dermatitis, and has a wide range of application prospects.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention provides bacillus mojavensis and belongs to the technical field of microorganisms. The preservation number of the bacillus mojavensis VT275 is CGMCC (China General Microbiological Culture Collection Center) No.29974. The bacillus mojavensis VT275 can be used for effectively inhibiting common skin pathogenic bacteria and food-borne pathogenic bacteria, such as staphylococcus aureus, methicillin-resistant staphylococcus aureus, staphylococcus epidermidis, listeria monocytogenes, shigella, enterococcus faecalis and the like. The bacillus mojavensis VT275 disclosed by the invention can be used for preventing or treating skin diseases such as specific dermatitis or controlling food-borne infection, and has a good application prospect in the fields of medicines, cosmetics, edible microorganisms, feed microorganisms and the like.
Need to check novelty before this filing date? Find Prior Art